Enzalutamide is a potent androgen receptor inhibitor that blocks the action of testosterone in prostate tumour cells, slowing tumour progression. It is effective in both early and advanced stages of prostate cancer.
Recommended for:
Patients with castration-resistant prostate cancer (CRPC)
Men with metastatic hormone-sensitive prostate cancer (mHSPC)
Individuals undergoing or post androgen-deprivation therapy
Non-surgical candidates with progressing disease
Used in adult men for the treatment of metastatic or castration-resistant prostate cancer.
Take orally once daily at the same time, with or without food. The dosage and treatment duration should be determined by a healthcare professional.
Contraindications:
Hypersensitivity to enzalutamide
Severe hepatic impairment
History of seizures
Women and children
Side Effects:
Fatigue, headache
Increased blood pressure
Hot flushes, back pain
Rare seizures, anxiety
Elevated blood lipid levels
